Silverarc Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Silverarc Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-117,485	Closed	-$5.44M	–	89
2025 Q4	$5.44M	Buy	+117,485	New	+$6.44M	0.76%	36
2025 Q3	–	Sell	-204,591	Closed	-$17.1M	–	94
2025 Q2	$17.1M	Buy	204,591 +38,174	+23%	+$2.86M	3.16%	13
2025 Q1	$11.9M	Buy	+166,417	New	+$8.1M	2.43%	12
2024 Q3	–	Sell	-15,000	Closed	-$612K	–	81
2024 Q2	$612K	Buy	+15,000	New	+$636K	0.14%	64
2024 Q1	–	Sell	-73,665	Closed	-$2.97M	–	94
2023 Q4	$2.97M	Sell	73,665 -296,335	-80%	-$8.43M	0.88%	42
2023 Q3	$10.9M	Buy	+370,000	New	+$2.24M	3.31%	5
2021 Q2	–	Sell	-8,333	Closed	-$158K	–	111
2021 Q1	$158K	Sell	8,333 -13,187	-61%	-$425K	0.09%	86
2020 Q4	$623K	Buy	+21,520	New	+$621K	0.36%	65

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Silverarc Capital Management's SLNO Position: Q1 2026 in Review

Silverarc Capital Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 117,485 shares — an estimated $5.44M sold.

Silverarc Capital Management first reported a position in SLNO in Q4 2020 and held it in 8 quarters. The position peaked at $17.1M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Silverarc Capital Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
Silverarc Capital Management sold 117,485 Soleno Therapeutics shares in Q1 2026, an estimated $5.44M.
Silverarc Capital Management first reported a position in Soleno Therapeutics in Q4 2020 and held it in 8 quarters.
Silverarc Capital Management's Soleno Therapeutics position peaked at $17.1M in Q2 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.